Visterra inks drug development pact with Scangos startup worth up to $1B
October 18, 2017 at 07:01 AM EDT
The Cambridge biotech said it would license some of its experimental infectious disease drugs to San Francisco-based Vir Biotechnology, which is led by former Biogen CEO George Scangos.
